Exact Mass: 416.2363
Exact Mass Matches: 416.2363
Found 500 metabolites which its exact mass value is equals to given mass value 416.2363
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Distigmine
ATC code: N07AA03
Ramipril
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Ramipril
Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
CPA(18:2(9Z,12Z)/0:0)
cPA(18:2(9Z,12Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis. [HMDB] cPA(18:2(9Z,12Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis.
Forasartan
Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance. C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
Elarofiban
Glutamylleucylarginine
Zabicipril
AL 8810 Methyl ester
Distigmine
N - Nervous system > N07 - Other nervous system drugs > N07A - Parasympathomimetics > N07AA - Anticholinesterases D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D004791 - Enzyme Inhibitors
(5S,6E,10R)-5-beta-D-glucopyranosyloxy-3,10-dihydroxy-3,7,11-trimethyldodeca-1,5,11-triene|amarantholidoside II
(1S,4S,5R,7R,10R)-11,14-dihydroxyguai-3-one 11-O-beta-D-glucopyranoside|(1S,4S,5R,7R,10R)-11,14-Dihydroxyguai-3-one 11-O-??-D-glucopyranoside|(1S,4S,5R,7R,10R)-11,14-dihydroxyguaian-3-one 11-O-beta-D-glucopyranoside
(11S)-7-eudesmene-1beta,4beta,12-triol 1-O-beta-D-glucopyranose|iwayoside C
(5Z)-6-[5-(2-beta-D-glucopyranosyloxy-propan-2-yl)-2-methyltetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-ol|shanyeside B
1-hydroperoxy-7,10-dihydroxybisabola-2,11-diene 7-beta-D-fucopyranoside
1-hydroperoxy-7,12-dihydroxybisabola-2,10-diene 7-beta-D-fucopyranoside
muurol-4-ene-1beta,3beta,10beta-triol 3-O-beta-D-glucopyranoside|rel-(2R,4aS,5R,8R,8aS)-1,2,4a,5,6,7,8,8a-octahydro-8,8a-dihydroxy-3,8-dimethyl-5-(1-methylethyl)naphthalen-2-yl beta-D-glucopyranoside
muurol-4-ene-1beta,3beta,15-triol 3-O-beta-D-glucopyranoside|rel-(2R,4aS,5R,8S,8aR)-1,2,4a,5,6,7,8,8a-octahydro-8a-hydroxy-3-(hydroxymethyl)-8-methyl-5-(1-methylethyl)naphthalen-2-yl beta-D-glucopyranoside
beta-methyl-15-hydroxymethylfaurinone-9-alpha-O-beta-D-glucoside|cupressusoside
(5Z)-6-[5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-O-beta-D-glucopyranoside
(5S,6E,9E)-5-beta-D-glucopyranosyloxy-3,11-dihydroxy-3,7,11-trimethyldodeca-1,6,9-triene|amarantholidoside I
1beta,6beta,9alpha-trihydroxy-trans-eudesm-3-ene-6-O-beta-D-glucopyranoside
1-acetyl-15,16-dimethoxy-aspidospermidine-17,21-diol|N-Acetyl-N-depropionyl-aspido-albinol
2alpha,7-dihydroxykessane 2-O-beta-D-glucopyranoside
Ala Ala Lys Gln
Ala Ala Gln Lys
Ala Asp Ile Val
Ala Asp Leu Val
Ala Asp Val Ile
Ala Asp Val Leu
Ala Glu Val Val
Ala Ile Asp Val
Ala Ile Val Asp
Ala Lys Ala Gln
Ala Lys Gln Ala
Ala Leu Asp Val
Ala Leu Val Asp
Ala Gln Ala Lys
Ala Gln Lys Ala
Ala Val Asp Ile
Ala Val Asp Leu
Ala Val Glu Val
Ala Val Ile Asp
Ala Val Leu Asp
Ala Val Val Glu
Asp Ala Ile Val
Asp Ala Leu Val
Asp Ala Val Ile
Asp Ala Val Leu
Asp Gly Ile Ile
Asp Gly Ile Leu
Asp Gly Leu Ile
Asp Gly Leu Leu
Asp Ile Ala Val
Asp Ile Gly Ile
Asp Ile Gly Leu
Asp Ile Ile Gly
Asp Ile Leu Gly
Asp Ile Val Ala
Asp Leu Ala Val
Asp Leu Gly Ile
Asp Leu Gly Leu
Asp Leu Ile Gly
Asp Leu Leu Gly
Asp Leu Val Ala
Asp Val Ala Ile
Asp Val Ala Leu
Asp Val Ile Ala
Asp Val Leu Ala
Glu Ala Val Val
Glu Gly Ile Val
Glu Gly Leu Val
Glu Gly Val Ile
Glu Gly Val Leu
Glu Ile Gly Val
Glu Ile Val Gly
Glu Leu Gly Val
Glu Leu Val Gly
Glu Val Ala Val
Glu Val Gly Ile
Glu Val Gly Leu
Glu Val Ile Gly
Glu Val Leu Gly
Glu Val Val Ala
Gly Asp Ile Ile
Gly Asp Ile Leu
Gly Asp Leu Ile
Gly Asp Leu Leu
Gly Glu Ile Val
Gly Glu Leu Val
Gly Glu Val Ile
Gly Glu Val Leu
Gly Gly Lys Arg
Gly Gly Arg Lys
Gly Ile Asp Ile
Gly Ile Asp Leu
Gly Ile Glu Val
Gly Ile Ile Asp
Gly Ile Leu Asp
Gly Ile Val Glu
Gly Lys Gly Arg
Gly Lys Asn Val
Gly Lys Arg Gly
Gly Lys Val Asn
Gly Leu Asp Ile
Gly Leu Asp Leu
Gly Leu Glu Val
Gly Leu Ile Asp
Gly Leu Leu Asp
Gly Leu Val Glu
Gly Asn Lys Val
Gly Asn Val Lys
Gly Arg Gly Lys
Gly Arg Lys Gly
Gly Val Glu Ile
Gly Val Glu Leu
Gly Val Ile Glu
Gly Val Lys Asn
Gly Val Leu Glu
Gly Val Asn Lys
Ile Ala Asp Val
Ile Ala Val Asp
Ile Asp Ala Val
Ile Asp Gly Ile
Ile Asp Gly Leu
Ile Asp Ile Gly
Ile Asp Leu Gly
Ile Asp Val Ala
Ile Glu Gly Val
Ile Glu Val Gly
Ile Gly Asp Ile
Ile Gly Asp Leu
Ile Gly Glu Val
Ile Gly Ile Asp
Ile Gly Leu Asp
Ile Gly Val Glu
Ile Ile Asp Gly
Ile Ile Gly Asp
Ile Leu Asp Gly
Ile Leu Gly Asp
Ile Pro Ser Thr
Ile Pro Thr Ser
Ile Ser Pro Thr
Ile Ser Thr Pro
Ile Thr Pro Ser
Ile Thr Ser Pro
Ile Val Ala Asp
Ile Val Asp Ala
Ile Val Glu Gly
Ile Val Gly Glu
Lys Ala Ala Gln
Lys Ala Gln Ala
Lys Gly Gly Arg
Lys Gly Asn Val
Lys Gly Arg Gly
Lys Gly Val Asn
Lys Asn Gly Val
Lys Asn Val Gly
Lys Gln Ala Ala
Lys Arg Gly Gly
Lys Val Gly Asn
Lys Val Asn Gly
Leu Ala Asp Val
Leu Ala Val Asp
Leu Asp Ala Val
Leu Asp Gly Ile
Leu Asp Gly Leu
Leu Asp Ile Gly
Leu Asp Leu Gly
Leu Asp Val Ala
Leu Glu Gly Val
Leu Glu Val Gly
Leu Gly Asp Ile
Leu Gly Asp Leu
Leu Gly Glu Val
Leu Gly Ile Asp
Leu Gly Leu Asp
Leu Gly Val Glu
Leu Ile Asp Gly
Leu Ile Gly Asp
Leu Leu Asp Gly
Leu Leu Gly Asp
Leu Pro Ser Thr
Leu Pro Thr Ser
Leu Ser Pro Thr
Leu Ser Thr Pro
Leu Thr Pro Ser
Leu Thr Ser Pro
Leu Val Ala Asp
Leu Val Asp Ala
Leu Val Glu Gly
Leu Val Gly Glu
Asn Gly Lys Val
Asn Gly Val Lys
Asn Lys Gly Val
Asn Lys Val Gly
Asn Val Gly Lys
Asn Val Lys Gly
Pro Ile Ser Thr
Pro Ile Thr Ser
Pro Leu Ser Thr
Pro Leu Thr Ser
Pro Ser Ile Thr
Pro Ser Leu Thr
Pro Ser Thr Ile
Pro Ser Thr Leu
Pro Thr Ile Ser
Pro Thr Leu Ser
Pro Thr Ser Ile
Pro Thr Ser Leu
Pro Thr Thr Val
Pro Thr Val Thr
Pro Val Thr Thr
Gln Ala Ala Lys
Gln Ala Lys Ala
Gln Lys Ala Ala
Arg Gly Gly Lys
Arg Gly Lys Gly
Arg Lys Gly Gly
Ser Ile Pro Thr
Ser Ile Thr Pro
Ser Leu Pro Thr
Ser Leu Thr Pro
Ser Pro Ile Thr
Ser Pro Leu Thr
Ser Pro Thr Ile
Ser Pro Thr Leu
Ser Thr Ile Pro
Ser Thr Leu Pro
Ser Thr Pro Ile
Ser Thr Pro Leu
Thr Ile Pro Ser
Thr Ile Ser Pro
Thr Leu Pro Ser
Thr Leu Ser Pro
Thr Pro Ile Ser
Thr Pro Leu Ser
Thr Pro Ser Ile
Thr Pro Ser Leu
Thr Pro Thr Val
Thr Pro Val Thr
Thr Ser Ile Pro
Thr Ser Leu Pro
Thr Ser Pro Ile
Thr Ser Pro Leu
Thr Thr Pro Val
Thr Thr Val Pro
Thr Val Pro Thr
Thr Val Thr Pro
Val Ala Asp Ile
Val Ala Asp Leu
Val Ala Glu Val
Val Ala Ile Asp
Val Ala Leu Asp
Val Ala Val Glu
Val Asp Ala Ile
Val Asp Ala Leu
Val Asp Ile Ala
Val Asp Leu Ala
Val Glu Ala Val
Val Glu Gly Ile
Val Glu Gly Leu
Val Glu Ile Gly
Val Glu Leu Gly
Val Glu Val Ala
Val Gly Glu Ile
Val Gly Glu Leu
Val Gly Ile Glu
Val Gly Lys Asn
Val Gly Leu Glu
Val Gly Asn Lys
Val Ile Ala Asp
Val Ile Asp Ala
Val Ile Glu Gly
Val Ile Gly Glu
Val Lys Gly Asn
Val Lys Asn Gly
Val Leu Ala Asp
Val Leu Asp Ala
Val Leu Glu Gly
Val Leu Gly Glu
Val Asn Gly Lys
Val Asn Lys Gly
Val Pro Thr Thr
Val Thr Pro Thr
Val Thr Thr Pro
Val Val Ala Glu
Val Val Glu Ala
Forasartan
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(triMethylsilyl)ethoxy)Methyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone
1-BOC-4-[4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-BENZOYL]-PIPERAZINE
tert-butyl 4-[[2-(5-amino-3-methyl-1H-pyrazol-4-yl)-6-methoxy-phe noxy]methyl]piperidine-1-carboxylate
tert-Butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)piperazine-1-carboxylate
Tonapofylline
C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator Tonapofylline (BG 9928) is an orally active and selective adenosine A1 receptor antagonist with a Ki of 7.4 nM for human adenosine A1 receptor (hA1), which displays 915-fold selectivity versus human adenosine A2A receptor and 12-fold selectivity versus human adenosine A2B receptor and is used in development for the treatment of heart failure[1][2].
Trecetilide
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent
N-(3-Amino-4-chlorophenyl)-2-(2,4-di-tert-pentylphenoxy)acetamide
(2S,3aR,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
3-(6-ethoxynaphthalen-2-yl)-1-((1-methylpiperidin-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
(3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
5-Benzyl-2,3-bis(4-methoxyphenyl)-1,4-dimethylpiperazine
1-(9Z,12Z)-octadecadienylglycerone 3-phosphate(2-)
3-[[(1,3-dimethyl-4-pyrazolyl)methyl-methylamino]methyl]-N-methyl-N-(phenylmethyl)-2-imidazo[1,2-a]pyridinecarboxamide
N-[(2S,3R,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3R,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3R,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3R,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3S,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3S,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3S,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3S,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(1-oxo-2-phenylethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide
1-(9Z,12Z,15Z)-octadecatrienylglycerone 3-phosphate
A 1-alkylglycerone 3-phosphate in which the alkyl group is specified as (9Z,12Z,15Z)-octadecatrienyl.
1-(9Z,12Z)-octadecadienylglycerone 3-phosphate(2-)
A 1-alkylglycerone 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-(9Z,12Z)-octadecadienylglycerone 3-phosphate; major species at pH 7.3.
GR 125743
GR 125743 is a selective 5-HT1B/1D receptor antagonist, with pKis of 8.85 and 8.31 for wild-type h5-HT1B and wild-type h5-HT1D, respectively. GR 125743 is used for the research of Parkinson's disease and cardiovascular diseases[1][2].
(3s,6s,12s)-12-benzyl-5,11-dihydroxy-1,6,7-trimethyl-3-(2-methylpropyl)-1,4,7,10-tetraazacyclododeca-4,10-diene-2,8-dione
(2s,3r,4s,5s,6r)-2-{[(1s,2s,4ar,6r,7s,8ar)-1,6-dihydroxy-1,4a-dimethyl-7-(prop-1-en-2-yl)-octahydronaphthalen-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
3,10,12,16-tetramethyl-14-methylidene-15,17-dioxo-18,20-dioxatetracyclo[11.5.2.0¹,⁶.0¹⁶,¹⁹]icos-4-ene-4-carboxylic acid
1-(2,6-dihydroxy-4-methoxyphenyl)-11-(2,6-dihydroxyphenyl)undecan-1-one
2-(acetyloxy)-5,5,9-trimethyl-14-methylidene-10,15-dioxotricyclo[11.2.1.0⁴,⁹]hexadec-1(16)-en-11-yl acetate
(1r,4as,5r,6as,11ar,11br)-1-(acetyloxy)-4a-hydroxy-4,4,11b-trimethyl-7-methylidene-1h,2h,3h,5h,6h,6ah,11h,11ah-phenanthro[3,2-b]furan-5-yl acetate
2-[2-(acetyloxy)ethenyl]-6,10-dimethyl-14-methylidene-12,15-dioxopentadeca-1,5,9-trien-1-yl acetate
(3z,3as,5ar,6r,7r,9ar,9bs)-7-(acetyloxy)-3a,6,9a-trimethyl-2-oxo-3-(5-oxopent-3-en-2-ylidene)-octahydrocyclopenta[a]naphthalene-6-carboxylic acid
(2r,3r,4s,5s,6r)-2-{[(1s,1ar,3ar,4s,7r,7as,7bs)-4-hydroxy-1-(hydroxymethyl)-1,7-dimethyl-octahydro-1ah-cyclopropa[a]naphthalen-4-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2r,3s,4s,5s,6s)-2-{[(1r,1ar,4s,4as,7r,7as,7bs)-4-hydroxy-1-(hydroxymethyl)-1,7-dimethyl-octahydro-1ah-cyclopropa[e]azulen-4-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1s,2r,5s,6s,7s,9r,12r)-5-(acetyloxy)-12-hydroxy-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate
16-hydroxy-9-isopropyl-2,5,13,16-tetramethyl-6,15,19-trioxatetracyclo[12.5.1.0⁵,¹⁰.0¹⁷,²⁰]icosa-1,9,12-triene-7,18-dione
2-{[2-(6,7-dihydroxy-4a-methyl-8-methylidene-octahydronaphthalen-2-yl)propan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
3-[(1r,2r,4ar,6s,8as)-2-hydroxy-1,2,6-trimethyl-4a,5,6,7,8,8a-hexahydronaphthalen-1-yl]-3-oxopropyl 2-(3,4-dihydroxyphenyl)acetate
7-{[(2e,6e,10r)-10,11-dihydroxy-3,7,11-trimethyldodeca-2,6-dien-1-yl]oxy}-5-hydroxychromen-2-one
4,6-dihydroxy-7-isopropyl-4a-methyl-1-methylidene-octahydronaphthalen-2-yl 3-(3,4-dihydroxyphenyl)prop-2-enoate
2-{[1,6-dihydroxy-1,4a-dimethyl-7-(prop-1-en-2-yl)-octahydronaphthalen-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1s,3as,4r,7r,8ar)-4-(hydroxymethyl)-1-methyl-7-(2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2-yl)-octahydro-1h-azulen-2-one
(2s,4ar,4bs,5r,6as,10as,10bs,12as)-5-hydroxy-2,4b,7,7,10a,12a-hexamethyl-12-methylidene-octahydrophenanthro[1,2-c]pyran-1,4,6,8-tetrone
2-{[2,4-dihydroxy-4,8a-dimethyl-6-(prop-1-en-2-yl)-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
1-(acetyloxy)-3-hydroxy-3-isopropyl-6,8a-dimethyl-1,2,3a,4,5,8-hexahydroazulen-4-yl 4-hydroxybenzoate
(2r,3r,4s,5s,6r)-2-{[(3s,5s,6e,9e)-3,11-dihydroxy-3,7,11-trimethyldodeca-1,6,9-trien-5-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
10β,13,14-trihydroxyalloaromadendrane
{"Ingredient_id": "HBIN000059","Ingredient_name": "10\u03b2,13,14-trihydroxyalloaromadendrane","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC1CCC2C1C3C(C3(C)CO)CCC2(COC4C(C(C(C(O4)CO)O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "42560","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(1s,4s,5r,7r,10r)-11,14-dihydroxyguai-3-one11-o-β-d-glucopyranoside
{"Ingredient_id": "HBIN003289","Ingredient_name": "(1s,4s,5r,7r,10r)-11,14-dihydroxyguai-3-one11-o-\u03b2-d-glucopyranoside","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC1C2CC(CCC(C2CC1=O)CO)C(C)(C)OC3C(C(C(C(O3)CO)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15108","TCMID_id": "5901","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
alatoside a
{"Ingredient_id": "HBIN015044","Ingredient_name": "alatoside a","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC(=C)C1CCC2(C(C1)C(CC(C2OC3C(C(C(C(O3)CO)O)O)O)O)(C)O)C","Ingredient_weight": "416.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "838","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "11144190","DrugBank_id": "NA"}
atractyloside g
{"Ingredient_id": "HBIN017307","Ingredient_name": "atractyloside g","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC12CCC(CC1C(=C)C(C(C2)O)O)C(C)(C)OC3C(C(C(C(O3)CO)O)O)O","Ingredient_weight": "416.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT14423","TCMID_id": "1979","TCMSP_id": "NA","TCM_ID_id": "6487","PubChem_id": "101831405","DrugBank_id": "NA"}